Tables & Figures
- Table 1.1 Top Ten Bacterial Organisms Isolated From Different Clinical Specimens in 2023. Data From the Hospital Authority.
- Table 1.2 Intrinsic and Associated Resistance to Antimicrobial Agents Among Five Nosocomial Pathogens
- Table 1.3 Non-Susceptibility of Common Bacterial Isolates From Blood Specimens in HA Hospitals in 2023
- Table 1.4 Estimates of Microorganisms Significantly Associated With AMR, Hong Kong, 2019–2023
- Table 1.5 Characteristics of Vancomycin-Resistant Enterococcus faecium, CC17
- Table 1.6 Characteristics of ESBL and AmpC β-Lactamases
- Table 1.7 Different Classes of Carbapenemase
- Table 2.1 Roles of OPAT Team Members
- Table 2.2 Main Bundle Components of OPAT
- Table 3.1 Summary of the Mechanisms of Selected Antifungals and Their General Spectrum of Activity
- Table 4.1 Interpretation of Penicillin Susceptibility for Streptococcus pneumoniae
- Table 4.2 Comparative Activities of Commonly Used β-Lactams Against Streptococcus pneumoniae With Different Levels of Penicillin Susceptibility
- Table 6.1 Dosing and Redosing Intervals for Surgical Prophylaxis
- Table 7.1 Low- and High-Risk Features During the Evaluation of Penicillin Allergy
- Table 7.2 Cross-Reacting Side Chains Between β-Lactam Antibiotics
- Table 7.3 Antimicrobial Agents for Outpatient Therapy of Uncomplicated CA-MRSA SSTI
- Figure 1.1 Distribution of MIC for Vancomycin Against 963 MRSA Isolated from Blood Cultures in KCC, KEC and HKWC, 2020–2023
- Figure 1.2 Number of CA-MRSA Reported to the CHP From 2007–2024
- Figure 1.3 Burden for ESBL-Producing Escherichia coli Bacteraemia in a Regional Hospital in Hong Kong
- Figure 1.4 Carbapenemase-Producing Enterobacterales (CPE) in Hong Kong, 2019 to 2023. (A) Number of Patients With CPE per Year, (B) Proportion of Carbapenemase Types Among CPE Isolates.
- Figure 1.5 Prevalence of Mycoplasma pneumoniae in Respiratory Specimens According to Patient Age Groups, All HA Hospitals, 2023
- Figure 1.6 Prevalence of Macrolide Resistance Among Mycoplasma pneumoniae, QMH.
- Figure 1.7 Resistance Trends of Escherichia coli, Klebsiella spp., and Enterococcus in Blood and Non-Blood Specimens (2008–2023)
- Figure 3.1 Species Distribution of Fungaemia Patients in the Hospital Authority (2019–2023)
- Figure 4.1 Susceptibility of Invasive Pneumococcal Isolates to Penicillin and Cefotaxime According to Patient Age Groups
- Figure 7.1 Summary of the Asia Pacific Clinical Pathway on Direct DPT for Penicillin Allergy
- Figure 7.2 Flowchart for the Clinical Management of Suspected/Confirmed CA-MRSA Infections
- Figure 7.3 Susceptibility of CA-MRSA Isolates to Five Common Antimicrobial Agents